-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The recurrence of rhabdomyosarcoma (RMS) generally means the appearance of refractory disease, leading to poor survival (OS)
.
Recently, the European research team launched a phase II study VIT-0910 to evaluate the efficacy and safety of vincristine + irinotecan with or without temozolomide in the treatment of relapsed or refractory rhabdomyosarcoma
The recurrence of rhabdomyosarcoma (RMS) generally means the appearance of refractory disease, leading to poor survival (OS)
The VIT-0910 study is an international, open-label, randomized phase II trial
.
The primary study endpoint was the objective response rate (ORR) after 2 cycles, and the secondary study endpoints were PFS, OS, and adverse events
The VIT-0910 study is an international, open-label, randomized phase II trial
The study included 120 patients, 60 patients in the two groups
Compared with the VI group, the VIT group significantly prolonged the overall survival (OS) of patients (adjusted HR=0.
PFS and OS
PFS and OSThe proportion of ≥3 grade adverse events in the VIT group and the VI group were 98% and 78%, respectively, and there was a significant statistical difference (p=0.
009)
.
Similarly, for any grade of adverse events, the VIT group increased significantly compared with the VI group
The proportion of ≥3 grade adverse events in the VIT group and the VI group were 98% and 78%, respectively, and there was a significant statistical difference (p=0.
Adverse events
Adverse eventsIn summary: vincristine + irinotecan combined with temozolomide can improve the prognosis of patients with relapsed or refractory rhabdomyosarcoma, and the toxicity is tolerable
.
VIT can be used as a new treatment
In summary: vincristine + irinotecan combined with temozolomide can improve the prognosis of patients with relapsed or refractory rhabdomyosarcoma, and the toxicity is tolerable
Original source:
Defachelles AS, Bogart E, Casanova M, et al.
Defachelles AS, Bogart E, Casanova M, et al.
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
J Clin Oncol.
2021 Aug 3: JCO2100124.
doi: 10.
1200/JCO.
21.
00124.
Epub ahead of print.
PMID: 34343032.
Leave a message here
